Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021. In conjunction with the release, the Company will host a conference call and webcast tha...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 202...
Personalis (PSNL) announces a collaboration with MapKure to use a clinical trial assay ((CTA)) based on the Personalis NeXT Platform to support development of BGB-3245 in patients with advanced or refractory solid tumors.MapKure is a clinical-stage company focusing on genetically defined...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has appointed Dr. Woodrow (Woody) Myers to its Board of Directors and to the Nominating and Corporate Governance Committee of the Board. The company also announce...
Personalis, Inc. (PSNL) Q4 2020 Earnings Conference Call February 25, 2021 17:00 ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of Ameri...
Personalis (PSNL): Q4 GAAP EPS of -$0.34 misses by $0.04.Revenue of $20.18M (+11.2% Y/Y) beats by $0.16M.2021 Guidance: Revenues to be ~$20.3M; revenues from biopharma and all other customers, excluding VA MVP, to be in the range of $5.6-$7M and net loss of $14-$15M.Shares -6.88%.Press R...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter Highlights Record quarterly revenue of $20.2 million in the fo...
Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 5065084. (instead of Interested pa...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...